# Comprehensive pan-cancer analysis of RPRD1B as a promising diagnostic and prognostic biomarker

## TL;DR

This study identifies RPRD1B as a potential biomarker for diagnosing and predicting cancer outcomes across multiple cancer types.

## Contribution

The study provides the first comprehensive pan-cancer analysis of RPRD1B's role in cancer progression and prognosis.

## Key findings

- RPRD1B is upregulated in most tumor types compared to normal tissues.
- High RPRD1B expression correlates with immune cell infiltration and cancer prognosis.
- Knocking down RPRD1B suppresses tumor growth in colon adenocarcinoma.

## Abstract

Regulation of nuclear pre-mRNA domain containing 1B (RPRD1B, also known as CREPT), has emerged as a potential factor in cancer development. Despite growing evidence, a comprehensive evaluation of RPRD1B across different cancer types has not been conducted. This study aims to explore its prognostic significance in pan-cancer analysis.

Online databases and platforms such as The Cancer Genome Atlas (TCGA), Genotype Tissue Expression (GTEx), the Human Protein Atlas (HPA), cBioPortal, TIMER2.0, BioGRID, and SangerBox were used to gather data on RPRD1B across various cancers. The pan-cancer patient datasets were analyzed to explore the relationships among RPRD1B expression, genetic alterations, protein interactions, tumor immunity, and clinical features.

The findings indicate that RPRD1B was upregulated in most tumor types compared to normal tissues, and increased protein levels observed in several cancers. Notably, high RPRD1B expression was associated with the infiltration of immune cells, endothelial cells, and cancer-associated fibroblasts (CAFs), as well as the expression of tumor immune markers in certain cancers. Additionally, elevated RPRD1B expression proved useful for aiding cancer diagnosis and predicting prognosis across multiple cancer types. In vitro studies showed that RPRD1B was upregulated in colon adenocarcinoma (COAD) cell lines, where it promoted cell proliferation and invasion. In vivo experiments further demonstrated that knocking down RPRD1B significantly suppressed tumor growth.

High RPRD1B expression contributes to cancer progression and may function as a key biomarker for the diagnosis and prognosis across various tumor types.